Cardiff Oncology Inc (CRDF) Live Share Price, Invest From India

Cardiff Oncology Inc Stock Performance

as on May 30, 2026 at 6:59 am IST

Day's Low
$1.82
Day's Price Range
$1.91
$1.91
4.71%
Downside
52 Week's Low
52 Week's High
$1.48
52-Week Price Range
$4.56
$1.91
22.51%
Downside
138.48%
Upside

Cardiff Oncology Inc share price movements today

Previous Close: $1.84
Open: $1.85
Volume: 985.7K
Day's Low - High: $1.82 - $1.91
52 Week Low - High: $1.48 - $4.56

Cardiff Oncology Inc Historical Returns

1 Month Return: + 13.58 %
3 Month Return: -5.15 %
1 Year Return: -44.91 %
3 Year Return: + 10.84 %
5 Year Return: -78.1 %

Cardiff Oncology Inc Stock Fundamentals & Key Indicators

Check Cardiff Oncology Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$123.7M

EPS (TTM)

-0.6867

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-47.1M

Revenue (TTM)

525.0K

Profit Margin

0.00%

Return On Equity TTM

-84.79%

Cardiff Oncology Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Cardiff Oncology Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Cardiff Oncology Inc	BUY	$123.7M	-78.1%	NA	0.00%	NA
Alnylam Pharmaceuticals Inc	BUY	$39.5B	114.85%	74.09	12.55%	NA
Vertex Pharmaceuticals Inc	BUY	$111.0B	114.72%	25.98	35.51%	NA
Regeneron Pharmaceuticals Inc	BUY	$65.8B	23.7%	15.34	29.65%	0.5599999999999999%

Stock Returns calculator for Cardiff Oncology Inc Stock including INR - Dollar returns

The Cardiff Oncology Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Cardiff Oncology Inc investment value today

Current value as on today

₹63,600

Returns

-₹36,400

(-36.4%)

Returns from Cardiff Oncology Inc Stock

-₹42,814 (-42.81%)

Dollar Impact

₹6,415 (+6.41%)

Analyst Recommendation on Cardiff Oncology Inc Stock

Based on 10 analysts

BUY

90.00%

Buy

10.00%

Hold

0.00%

Sell

Based on 10 analysts, 90% of analysts recommend a 'BUY' rating for Cardiff Oncology Inc. Average target price of $7.69

Cardiff Oncology Inc Share Price Target

Get share price movements and forecasts by analysts on Cardiff Oncology Inc.

What analysts predicted

75.16%UPSIDE

Target Price

$7.69

Current Price

$1.91

Analyzed by

10 Analysts

Target

$7.69

Cardiff Oncology Inc target price $7.69, a slight upside of 75.16% compared to current price of $1.91. According to 10 analysts rating.

Indian Investors' Interest in Cardiff Oncology Inc Stock

Search interest for Cardiff Oncology Inc Stock has increased by 145% in the last 30 days, reflecting an upward trend in search activity.

Time period: April 30, 2026 to May 30, 2026

Change:145% versus previous 30 day period

Cardiff Oncology Inc Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	0	0	0	0	0	0	0	0	0	0
Gross Profit	0	0	0	-9	0	0	-11	0	0	0
Operating Income	-10	-10	-12	-12	-12	-14	-14	-11	-7	-12
EBITDA	-10	-10	-12	-12	-12	-14	-14	-10	-7	-12
Interest Expense	0	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-9	-10	-11	-11	-11	-13	-13	-11	-7	-12
Income Tax Expense	2	0	-	-	-	-	-	-	-	-
Net Income	-9	-10	-11	-11	-11	-13	-13	-11	-7	-12
Net Profit Margin	-5985.26%	-4883.41%	-7225.77%	-7184.85%	-7805.96%	-12324.77%	-11523.14%	-9381.67%	-2969.55%	-30124.39%

Cardiff Oncology Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	0	0	0	0	0	0	0	0	0	0
Gross Profit	-1	-1	0	0	0	0	0	0	0	0
Operating Income	-40	-25	-17	-16	-19	-28	-39	-45	-48	-48
EBITDA	-36	-22	-15	-15	-18	-28	-39	-45	-48	-48
Interest Expense	1	1	0	0	0	0	1	-	-	-
Depreciation	-	1	0	0	0	0	0	0	0	0
Income Before Tax	-39	-24	-16	-16	-19	-28	-38	-41	-45	-45
Income Tax Expense	0	0	0	0	0	0	-1	0	0	-
Net Income	-39	-24	-16	-16	-19	-28	-38	-41	-45	-45
Net Profit Margin	-10289.76%	-4932.08%	-4354.76%	-6709.74%	-5275.14%	-7880.50%	-10026.94%	-8492.01%	-6651.68%	-7732.04%

Cardiff Oncology Inc Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-10	-11	-11	-11	-13	-13	-11	-7	-12
Operating Cash Flow	-7	-9	-10	-10	-12	-8	-10	-5	-12
Investing Cash Flow	4	14	-9	4	-14	-4	10	10	3
Financing Cash Flow	0	2	7	44	0	-	0	2	0
Change in Cash	-2	6	-12	38	-27	-13	0	7	-8

Cardiff Oncology Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-24	-16	-16	-19	-28	-38	-41	-45	-45
Operating Cash Flow	-23	-13	-13	-16	-23	-33	-30	-37	-37
Investing Cash Flow	23	0	0	0	-131	38	36	13	1
Financing Cash Flow	-6	16	12	137	35	0	-	53	2
Change in Cash	-5	3	-1	120	-119	4	5	29	-34

Global Institutional Holdings in Cardiff Oncology Inc

Funds	Holdings
GSA Capital Partners LLP	0.31%
Geode Capital Management, LLC	2.34%
Geode Capital Management, LLC	2.23%
Charles Schwab Investment Management Inc	0.24%
The Goldman Sachs Group Inc	0.2%

See all

Insights on Cardiff Oncology Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 1 month, CRDF stock has moved up by 13.6%
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. Common Stock has given 62.0% return, outperforming this stock by 51.2%
NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. Common Stock has given 4.2% return, outperforming this stock by 49.1%
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, -7.21M → -12.35M (in $), with an average decrease of 71.2% per quarter
NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 243.0K → 41.0K (in $), with an average decrease of 83.1% per quarter

About Cardiff Oncology Inc

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Organisation	Cardiff Oncology Inc
Headquarters	11055 Flintkote Avenue, San Diego, CA, United States, 92121
Industry	Biotechnology
CEO	Dr. Mani Mohindru Ph.D.
E-voting on shares	Click here to vote

Key Management of Cardiff Oncology Inc

Name	Title
Mr. Josh Muntner BFA, M.B.A.	Chief Financial Officer
Dr. Ajay Aggarwal M.B.A., M.D.	Chief Operating Officer
Ms. Brigitte Lindsay	Chief Accounting Officer
Dr. Tod Smeal Ph.D.	Chief Scientific Officer
Ms. Elizabeth Anderson	VP of Finance & Administration
Dr. Mani Mohindru Ph.D.	President, CEO & Director
Dr. Roger Sidhu FRCPC, M.D.	Chief Medical Officer

FAQs

What is Cardiff Oncology Inc share price today?

Cardiff Oncology Inc share price today is $1.91 as on May 30, 2026 at 1:29 am IST at the close of the market. Cardiff Oncology Inc share today touched a day high of $1.91 and a low of $1.82.

What is the 52 week high and 52 week low for Cardiff Oncology Inc share?

Cardiff Oncology Inc share touched a 52 week high of $4.56 on July 18, 2025 and a 52 week low of $1.48 on February 5, 2026. Cardiff Oncology Inc stock price today i.e. May 30, 2026 at 1:29 am IST is closed at $1.91,which is 58.07% down from its 52 week high and 29.05% up from its 52 week low.

What is Cardiff Oncology Inc's market capitalisation today?

Cardiff Oncology Inc market capitalisation is $0.00T as on May 30, 2026 at 1:29 am IST.

How to invest in Cardiff Oncology Inc Stock (CRDF) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Cardiff Oncology Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Cardiff Oncology Inc Shares that will get you 0.7853 shares as per Cardiff Oncology Inc share price of $1.91 per share as on May 30, 2026 at 1:29 am IST.

What is the minimum amount required to buy Cardiff Oncology Inc Stock (CRDF) from India?

Indian investors can start investing in Cardiff Oncology Inc (CRDF) shares with as little as ₹95 or $1 (as of May 30, 2026 at 3:42 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹950.00 in Cardiff Oncology Inc stock (as per the Rupee-Dollar exchange rate as on May 30, 2026 at 3:42 am IST). Based on Cardiff Oncology Inc share’s latest price of $1.91 as on May 30, 2026 at 1:29 am IST, you will get 5.2356 shares of Cardiff Oncology Inc. Learn more about fractional shares .

What are the returns that Cardiff Oncology Inc has given to Indian investors in the last 5 years?

Cardiff Oncology Inc stock has given -78.1% share price returns and 31.96% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?